US Patent

US10052386 — Progesterone formulations

Formulation · Assigned to TherapeuticsMD Inc · Expires 2032-11-21 · 7y remaining

Vulnerability score 33/100 Strong — defensible against typical IPR challenges

What this patent protects

This patent protects various pharmaceutical formulations, including one comprising ultra-micronized progesterone.

USPTO Abstract

Various pharmaceutical formulations are disclosed herein. For example, a pharmaceutical formulation is disclosed comprising ultra-micronized progesterone.

Drugs covered by this patent

Patent Metadata

Patent number
US10052386
Jurisdiction
US
Classification
Formulation
Expires
2032-11-21
Drug substance claim
No
Drug product claim
Yes
Assignee
TherapeuticsMD Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.